The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro

Beiqing Pan, Luen Bik To, Amanda N. Farrugia, David M. Findlay, Jonathan Green, Stan Gronthos, Andreas Evdokiou, Kevin Lynch, Gerald J. Atkins, Andrew C W Zannettino

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Previous studies have attributed the increase in bone mass observed following bisphophonate (BP) therapy to their effects on bone-resorbing osteoclasts (OCs). However, recent evidence suggests that BPs can also act directly on bone forming osteoblasts (OBs) to increase their anabolic activity. Using an established model of in vitro OB differentiation, we found that the potent nitrogen-containing BP, zoledronic acid (ZOL), may enhance the bone forming potential of human adult OB-like cells in vitro by inducing their differentiation. ZOL dose dependently induced both cytostasis and cell death in OB-like cells at concentrations of 0.5 μM or greater. Cells expressing high levels of the osteoprogenitor antigen, STRO-1, exhibited a greater proliferative potential than STRO-1negative/dim cells, and were more susceptible to the cytostatic and apoptotic effects of ZOL. ZOL was also found to promote bone cell differentiation, as evidenced by an increase in the number of cells exhibiting a more differentiated (STRO-1-/AP+ and STRO-1-/AP-) phenotype. Analysis of gene expression, using semi-quantitative RT-PCR, demonstrated that ZOL treatment resulted in a significant upregulation of osteocalcin (OCN) and bone morphogenetic protein-2 (BMP-2) gene expression. Furthermore, in vitro mineralisation studies revealed that ZOL enhanced mineralised matrix formation at concentrations between 5 and 25 μM. These results show that, in addition to its direct effects on OCs, ZOL also directly affects the proliferation and differentiation of human OB-like cells in vitro and may enhance bone formation in vivo.

LanguageEnglish
Pages112-123
Number of pages12
JournalBone
Volume34
Issue number1
DOIs
Publication statusPublished - 1 Jan 2004

Keywords

  • Alkaline Phosphatase
  • Bisphosphonates
  • Bone mineralisation
  • Osteoblast-like cells
  • STRO-1
  • ZOL
  • Zoledronic acid

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Pan, Beiqing ; To, Luen Bik ; Farrugia, Amanda N. ; Findlay, David M. ; Green, Jonathan ; Gronthos, Stan ; Evdokiou, Andreas ; Lynch, Kevin ; Atkins, Gerald J. ; Zannettino, Andrew C W. / The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. In: Bone. 2004 ; Vol. 34, No. 1. pp. 112-123.
@article{0f946a9955914e4fa1ec6ebfc29f5b65,
title = "The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro",
abstract = "Previous studies have attributed the increase in bone mass observed following bisphophonate (BP) therapy to their effects on bone-resorbing osteoclasts (OCs). However, recent evidence suggests that BPs can also act directly on bone forming osteoblasts (OBs) to increase their anabolic activity. Using an established model of in vitro OB differentiation, we found that the potent nitrogen-containing BP, zoledronic acid (ZOL), may enhance the bone forming potential of human adult OB-like cells in vitro by inducing their differentiation. ZOL dose dependently induced both cytostasis and cell death in OB-like cells at concentrations of 0.5 μM or greater. Cells expressing high levels of the osteoprogenitor antigen, STRO-1, exhibited a greater proliferative potential than STRO-1negative/dim cells, and were more susceptible to the cytostatic and apoptotic effects of ZOL. ZOL was also found to promote bone cell differentiation, as evidenced by an increase in the number of cells exhibiting a more differentiated (STRO-1-/AP+ and STRO-1-/AP-) phenotype. Analysis of gene expression, using semi-quantitative RT-PCR, demonstrated that ZOL treatment resulted in a significant upregulation of osteocalcin (OCN) and bone morphogenetic protein-2 (BMP-2) gene expression. Furthermore, in vitro mineralisation studies revealed that ZOL enhanced mineralised matrix formation at concentrations between 5 and 25 μM. These results show that, in addition to its direct effects on OCs, ZOL also directly affects the proliferation and differentiation of human OB-like cells in vitro and may enhance bone formation in vivo.",
keywords = "Alkaline Phosphatase, Bisphosphonates, Bone mineralisation, Osteoblast-like cells, STRO-1, ZOL, Zoledronic acid",
author = "Beiqing Pan and To, {Luen Bik} and Farrugia, {Amanda N.} and Findlay, {David M.} and Jonathan Green and Stan Gronthos and Andreas Evdokiou and Kevin Lynch and Atkins, {Gerald J.} and Zannettino, {Andrew C W}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.bone.2003.08.013",
language = "English",
volume = "34",
pages = "112--123",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. / Pan, Beiqing; To, Luen Bik; Farrugia, Amanda N.; Findlay, David M.; Green, Jonathan; Gronthos, Stan; Evdokiou, Andreas; Lynch, Kevin; Atkins, Gerald J.; Zannettino, Andrew C W.

In: Bone, Vol. 34, No. 1, 01.01.2004, p. 112-123.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro

AU - Pan, Beiqing

AU - To, Luen Bik

AU - Farrugia, Amanda N.

AU - Findlay, David M.

AU - Green, Jonathan

AU - Gronthos, Stan

AU - Evdokiou, Andreas

AU - Lynch, Kevin

AU - Atkins, Gerald J.

AU - Zannettino, Andrew C W

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Previous studies have attributed the increase in bone mass observed following bisphophonate (BP) therapy to their effects on bone-resorbing osteoclasts (OCs). However, recent evidence suggests that BPs can also act directly on bone forming osteoblasts (OBs) to increase their anabolic activity. Using an established model of in vitro OB differentiation, we found that the potent nitrogen-containing BP, zoledronic acid (ZOL), may enhance the bone forming potential of human adult OB-like cells in vitro by inducing their differentiation. ZOL dose dependently induced both cytostasis and cell death in OB-like cells at concentrations of 0.5 μM or greater. Cells expressing high levels of the osteoprogenitor antigen, STRO-1, exhibited a greater proliferative potential than STRO-1negative/dim cells, and were more susceptible to the cytostatic and apoptotic effects of ZOL. ZOL was also found to promote bone cell differentiation, as evidenced by an increase in the number of cells exhibiting a more differentiated (STRO-1-/AP+ and STRO-1-/AP-) phenotype. Analysis of gene expression, using semi-quantitative RT-PCR, demonstrated that ZOL treatment resulted in a significant upregulation of osteocalcin (OCN) and bone morphogenetic protein-2 (BMP-2) gene expression. Furthermore, in vitro mineralisation studies revealed that ZOL enhanced mineralised matrix formation at concentrations between 5 and 25 μM. These results show that, in addition to its direct effects on OCs, ZOL also directly affects the proliferation and differentiation of human OB-like cells in vitro and may enhance bone formation in vivo.

AB - Previous studies have attributed the increase in bone mass observed following bisphophonate (BP) therapy to their effects on bone-resorbing osteoclasts (OCs). However, recent evidence suggests that BPs can also act directly on bone forming osteoblasts (OBs) to increase their anabolic activity. Using an established model of in vitro OB differentiation, we found that the potent nitrogen-containing BP, zoledronic acid (ZOL), may enhance the bone forming potential of human adult OB-like cells in vitro by inducing their differentiation. ZOL dose dependently induced both cytostasis and cell death in OB-like cells at concentrations of 0.5 μM or greater. Cells expressing high levels of the osteoprogenitor antigen, STRO-1, exhibited a greater proliferative potential than STRO-1negative/dim cells, and were more susceptible to the cytostatic and apoptotic effects of ZOL. ZOL was also found to promote bone cell differentiation, as evidenced by an increase in the number of cells exhibiting a more differentiated (STRO-1-/AP+ and STRO-1-/AP-) phenotype. Analysis of gene expression, using semi-quantitative RT-PCR, demonstrated that ZOL treatment resulted in a significant upregulation of osteocalcin (OCN) and bone morphogenetic protein-2 (BMP-2) gene expression. Furthermore, in vitro mineralisation studies revealed that ZOL enhanced mineralised matrix formation at concentrations between 5 and 25 μM. These results show that, in addition to its direct effects on OCs, ZOL also directly affects the proliferation and differentiation of human OB-like cells in vitro and may enhance bone formation in vivo.

KW - Alkaline Phosphatase

KW - Bisphosphonates

KW - Bone mineralisation

KW - Osteoblast-like cells

KW - STRO-1

KW - ZOL

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=9144233505&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2003.08.013

DO - 10.1016/j.bone.2003.08.013

M3 - Article

VL - 34

SP - 112

EP - 123

JO - Bone

T2 - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -